Get started
Author

See C. Phan

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
2021 · Stephen V. Liu, Martin Reck, et al. · Journal of Clinical Oncology · 860
PDF
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
2020 · Makoto Nishio, Fabrice Barlesi, et al. · Journal of Thoracic Oncology · 459
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
2017 · David R. Spigel, Martin J. Edelman, et al. · Journal of Clinical Oncology · 333
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
2016 · Manish A. Shah, Yung-Jue Bang, et al. · JAMA Oncology · 304
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
2021 · Jacek Jassem, Filippo de Marinis, et al. · Journal of Thoracic Oncology · 213
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
2022 · Edward S. Kim, Vamsidhar Velcheti, et al. · Nature Medicine · 181
PDF
Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial
2008 · Minesh P. Mehta, William R. Shapiro, et al. · International Journal of Radiation Oncology*Biology*Physics · 164
Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points
2002 · Minesh P. Mehta, William R. Shapiro, et al. · Journal of Clinical Oncology · 148
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
2018 · Nichola Cruickshanks, Ying Zhang, et al. · Clinical Cancer Research · 46
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer
2016 · Heather Wakelee, Zanete Zvirbule, et al. · Clinical Lung Cancer · 44
The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme
2004 · Rafael Manon, Susanta Hui, et al. · Technology in Cancer Research & Treatment · 42
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer
2016 · Fred R. Hirsch, Ramaswamy Govindan, et al. · Clinical Lung Cancer · 35
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.
2019 · Steven H. Lin, Yan Lin, et al. · Journal of Clinical Oncology · 16
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).
2020 · Jacek Jassem, Roy S. Herbst, et al. · Journal of Clinical Oncology · 13
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
2020 · Makoto Nishio, Fabrice Barlési, et al. · Journal of Thoracic Oncology · 10
Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC
2019 · Mark A. Socinski, Sarah M. Paul, et al. · Cancer Research · 8
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
2020 · Filippo de Marinis, Giuseppe Giaccone, et al. · Journal of Clinical Oncology · 5
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
2017 · Dwight Hall Owen, Paul A. Bunn, et al. · Journal of Clinical Oncology · 3
Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)
2020 · Leora Horn, Stephen V. Liu, et al. · Cancer Research · 2
PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST)
2016 · Mark A. Socinski, Joan Schiller, et al. · Journal of Thoracic Oncology · 2
PDF
Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC
2019 · Mark A. Socinski, Sarah M. Paul, et al. · Clinical Trials · 1
Supplementary Data from Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
2023 · Nichola Cruickshanks, Ying Zhang, et al.
Supplementary Data from Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
2023 · Nichola Cruickshanks, Ying Zhang, et al.
Data from Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
2023 · Nichola Cruickshanks, Ying Zhang, et al.
Data from Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
2023 · Nichola Cruickshanks, Ying Zhang, et al.
Works count: 32
Citation count: 2,889
H-index: 13
I10-index: 15
Year
Topic
Type